T-cell growth factors and the treatment of patients with cancer

Clin Immunol Immunopathol. 1992 Jan;62(1 Pt 2):S47-54. doi: 10.1016/0090-1229(92)90040-u.

Abstract

T-cell maturation has traditionally been felt to occur primarily within the thymus but it is now clear that dynamic processes in the periphery govern many functions such as T-cell activation, proliferation, tolerization, and migration into peripheral tissues. Four T-cell growth factors have now been identified. These include: interleukin-2 (IL-2), IL-4, IL-7, and a potent cofactor recently described, IL-10. These factors are believed to work synergistically in the fine regulation of the lymphoid pool. Both IL-2 and IL-4 have entered clinical trials with significant responses in the IL-2-based regimens of up to 40 to 50% in certain tumors. IL-7 and IL-10 are in preclinical studies. Although IL-2, IL-4, and IL-7 have been shown to induce lymphokine-activated killer cell activity from sensitive precursors, such studies have yet to be performed with IL-10.

Publication types

  • Review

MeSH terms

  • Humans
  • Interleukin-10 / therapeutic use*
  • Interleukin-2 / therapeutic use*
  • Interleukin-4 / therapeutic use*
  • Interleukin-7 / therapeutic use*
  • Killer Cells, Lymphokine-Activated / immunology
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • T-Lymphocytes / immunology

Substances

  • Interleukin-2
  • Interleukin-7
  • Interleukin-10
  • Interleukin-4